Day 2

Orion Therapeutics is a delivery platform-enabled RNA therapeutics company. We pair a proprietary lipid nanoparticle GENESYS™ delivery platform that entirely excludes ionizable cationic lipids with a vascular RNA therapy pipeline. Our safe, versatile, scalable, and targeted delivery platform can be leveraged across a broad range of disease applications to advance RNA therapies to market internally and in partnership.

Annate Bitherapeutics is developing a therapeutic platform that utilizes ApoL1, a naturally occurring component of the innate immune system. It is guided by our proprietary bispecific antibodies to become selectively lethal to cancer cells. This innovative mechanism complements existing therapies, with strong efficacy in multiple myeloma and promising preclinical results in pancreatic cancer models, demonstrating the platform’s broad potential across multiple tumor types.

Azome is developing first in class drugs to revolutionize the treatment of severe inflammatory diseases and injuries including bronchopulmonary dysplasia (BPD), acute respiratory distress syndrome (ARDS), exacerbations in idiopathic lung fibrosis (ILF), acute lung injury, acute kidney injury, and sepsis for which there are currently no preventative and a limited set of therapeutic options.

Empath Biosciences has developed a revolutionary drug discovery platform that overcomes barriers to scaling therapeutics from nature’s biodiversity, de-risks each step of the development process, and efficiently yields novel therapeutics. The lead, proof-of-principle chemical series is currently in IND-enabling studies and scheduled to be in the clinic in 2026.

GeneVentiv's AAV8.FVa gene therapy is the first universal gene therapy for all hemophilias and the first to treat inhibitor patients.

Verdant Scientific is developing a first-in-class, first-in-approach small molecule for the treatment of atopic dermatitis, more commonly known as eczema, which is poised to completely change the treatment of this chronic, inflammatory skin condition, which affects over 200 million people worldwide.

Alluminate is developing aluminum foil-based electrode materials for low-cost and high-performance solid-state batteries.

EarthEn develops thermo-mechanical, flexible, and future-proof long-duration energy storage that uses CO2 in a closed loop to potentially store 4 to over 100 hours of energy in a low-cost, highly scalable, and safe manner with a 30-year lifetime.